Skip to content

Lutetium-177 hydroxyapatite: a promising agent for treatment of long standing inflammatory knee arthritis

Lutetium-177 Hydroxyapatite Radiosynovectomy In Refractory Chronic Inflammatory Arthritis Of The Knee Joint

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/04/041884
Enrollment
29
Registered
2022-04-18
Start date
Unknown
Completion date
Unknown
Last updated
2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M658- Other synovitis and tenosynovitis

Interventions

Intervention1: Radiosynovectomy: Radiosynovectomy Intervention2: Radiosynovectomy: Radiosynovectomy will be performed on the knee joint by intra-articular injection of 177-Lutetium hydroxyapatite in t

Sponsors

AIIMS Jodhpur
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients with refractory chronic inflammatory arthritis of the knee joint with evidence of inflammation on bone scan. 2.Patients diagnosed with rheumatoid arthritis that are unresponsive to conventional medical treatment (NSAIDs, DMARDs, and/or biologicals) for at least 6 months, with predominant knee joint involvement. 3.Patients diagnosed with osteoarthritis unresponsive to conventional medical treatment (NSAIDs) for at least 6 months. 4.Patients suffering from hemophilia with at least 2 hemarthrosis of the knee joint in the past 6 months despite use of coagulation factors.

Exclusion criteria

Exclusion criteria: 1.Pregnant or breastfeeding women 2.Women planning to get pregnant within the next 6 months 3.Children 4.Local skin infection at the injection site 5.Suspected septic arthritis 6.Intra-articular fracture 7.Ruptured popliteal cyst 8.Severe joint instability due to bone destruction 9.Patients who have undergone arthroscopy or surgery of the affected knee joint within the past 6 weeks 10.Patients who have received radiosynovectomy for the involved knee joint within the last 6 months

Design outcomes

Primary

MeasureTime frame
To evaluate pain relief in patients receiving Lutetium-177 hydroxyapatite radiosynovectomy using Visual Analogue ScaleTimepoint: At 4 weeks and 12 weeks after radiosynovectomy

Secondary

MeasureTime frame
To assess improvement in signs of joint inflammation by bone scanTimepoint: Prior to radiosynovectomy, and at 12 weeks after radiosynovectomy;To compare the knee joint tenderness, analgesic use and mobility Timepoint: Prior to radiosynovectomy, and at 4 weeks and 12 weeks after radiosynovectomy;To evaluate the improvement in daily functioning using Oxford knee scoreTimepoint: Prior to radiosynovectomy, and at 12 weeks after radiosynovectomy

Countries

India

Contacts

Public ContactTanvi Sarwal

AIIMS Jodhpur

rajesh.nmd@gmail.com02912831467

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026